# Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II

> **NCT05764356** · — · NOT_YET_RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 2000 (estimated)

## Conditions studied

- Novel Oral Anticoagulants
- NOACs
- Rivaroxaban
- Apixaban
- Edoxaban
- Dabigatran
- Ticagrelor
- Pharmacodynamics
- Pharmacogenomics
- RNA Profile
- Bleeding
- Biomarker

## Interventions

- **GENETIC:** Detection of genotype and RNA profile in platelet and white blood cell
- **OTHER:** Indicators test related to coagulation function
- **OTHER:** Indicators test related to platelet function

## Key facts

- **NCT ID:** NCT05764356
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-03
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05764356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05764356, "Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05764356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*